+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Short-Read Sequencing - Global Strategic Business Report

  • PDF Icon

    Report

  • 88 Pages
  • December 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5304171
The global market for Short-Read Sequencing was estimated at US$19.8 Billion in 2023 and is projected to reach US$38.5 Billion by 2030, growing at a CAGR of 9.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Short-Read Sequencing Market - Key Trends and Drivers Summarized

How Is Short-Read Sequencing Transforming Genomics?

Short-read sequencing is a next-generation sequencing (NGS) technology that reads short fragments of DNA, typically between 100 and 300 base pairs. It is widely used in genomics for applications such as whole-genome sequencing, targeted sequencing, and RNA sequencing. Renowned for its high accuracy, scalability, and cost-effectiveness, short-read sequencing plays a critical role in research areas like cancer genomics, personalized medicine, and microbiome studies. As advancements in bioinformatics enhance data analysis capabilities, short-read sequencing continues to be a powerful tool for understanding genetic variation, disease mechanisms, and population genetics.

What Are the Key Segments in the Short-Read Sequencing Market?

Key technologies include Illumina sequencing and Ion Torrent sequencing, with Illumina sequencing holding a major share due to its high accuracy, extensive throughput, and broad application range. Applications span across oncology, infectious disease research, genetic testing, and agricultural genomics, with oncology accounting for a significant market share as cancer research and diagnostics rely heavily on DNA sequencing for precision medicine. End-users include research institutions, clinical laboratories, pharmaceutical companies, and academic centers, with research institutions leading the market due to their focus on genomics studies and disease research.

How Is Short-Read Sequencing Being Used Across Research and Clinical Applications?

In oncology, short-read sequencing is used for detecting somatic mutations, copy number variations, and gene fusions, facilitating personalized cancer treatment strategies. Infectious disease research leverages short-read sequencing to identify pathogens, track outbreaks, and study antimicrobial resistance, supporting public health initiatives. Genetic testing applications utilize short-read sequencing to identify genetic disorders, aiding in diagnostics and reproductive health management. In agriculture, short-read sequencing is applied in crop genomics and breeding programs to improve yield, resistance, and nutritional value. Additionally, the integration of bioinformatics and cloud computing has enhanced the analysis of large-scale sequencing data, enabling more accurate and faster genomic insights.

What Factors Are Driving the Growth in the Short-Read Sequencing Market?

The growth in the Short-Read Sequencing market is driven by several factors, including the increasing demand for genomic research in fields like oncology, infectious diseases, and personalized medicine. The growing focus on precision medicine, which relies heavily on genetic insights for tailored treatment, has accelerated the adoption of short-read sequencing in clinical settings. Advancements in sequencing technology, such as higher throughput and reduced costs, have made sequencing more accessible to a broader range of applications. The expanding use of bioinformatics tools and cloud-based data analysis has improved the efficiency of sequencing workflows, supporting broader adoption. Additionally, government funding for genomics research and the development of new diagnostic solutions have contributed to the growth of the short-read sequencing market.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Next-Generation Sequencing Technology segment, which is expected to reach US$25.0 Billion by 2030 with a CAGR of a 9.6%. The Sanger Sequencing Technology segment is also set to grow at 10.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $5.5 Billion in 2023, and China, forecasted to grow at an impressive 9.2% CAGR to reach $5.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Short-Read Sequencing Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Short-Read Sequencing Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Short-Read Sequencing Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players in the Global Short-Read Sequencing Market such as BGI Genomics Co Ltd., CD Genomics, Element Biosciences, Illumina, Inc., Integra Biosciences AG and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 32 companies featured in this Global Short-Read Sequencing market report include:

  • BGI Genomics Co Ltd.
  • CD Genomics
  • Element Biosciences
  • Illumina, Inc.
  • Integra Biosciences AG
  • MedGenome, Inc.
  • Oxford Nanopore Technologies, Ltd.
  • Pacific Biosciences of California, Inc.
  • seqWell
  • Thermo Fisher Scientific, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Short-Read Sequencing - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Demand for Next-Generation Sequencing (NGS) Spurs Growth in Short-Read Sequencing Market
  • Growing Focus on Genomics, Precision Medicine, and Personalized Therapies Expands Addressable Market
  • Expansion of Short-Read Sequencing in Oncology, Infectious Diseases, and Rare Genetic Disorders Fuels Market Growth
  • Increasing Adoption of Sequencing in DNA Methylation, RNA Sequencing, and Whole Genome Sequencing Expands Market Opportunities
  • Technological Innovations in Library Preparation, Data Analysis, and Bioinformatics Propel Market Expansion
  • Rising Focus on Complying with CLIA, CAP, and ISO Certifications Drives Demand for Short-Read Sequencing
  • Growing Use of Short-Read Sequencing in Drug Discovery, Biomarker Identification, and Microbiome Studies Expands Market Potential
  • Focus on Achieving Rapid Sequencing Turnaround, High Accuracy, and Lower Error Rates Strengthens Market for Short-Read Sequencing
  • Rising Adoption of Sequencing in Agriculture, Synthetic Biology, and Forensics Expands Addressable Market
  • Technological Advancements in Portable Sequencing Devices, Automation, and AI-Assisted Sequencing Propel Market Growth
  • Increasing Focus on Integrating Short-Read Sequencing with Population Genomics and Epidemiology Studies Drives Adoption
  • Rising Demand for Sequencing in Non-Invasive Prenatal Testing (NIPT), Liquid Biopsies, and Cell-Free DNA Analysis Strengthens Global Market
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Short-Read Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 2: World 7-Year Perspective for Short-Read Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • Table 3: World Recent Past, Current & Future Analysis for Next-Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 4: World 7-Year Perspective for Next-Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World 7-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 8: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 9: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 10: World 7-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World 7-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 14: World 7-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 15: World Recent Past, Current & Future Analysis for Pharma & Biotech Entities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 16: World 7-Year Perspective for Pharma & Biotech Entities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World 7-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 20: World 7-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 21: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 22: World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 23: World Short-Read Sequencing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 24: USA Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 25: USA 7-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2024 & 2030
  • Table 26: USA Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: USA 7-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2024 & 2030
  • Table 28: USA Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 29: USA 7-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2024 & 2030
CANADA
  • Table 30: Canada Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 31: Canada 7-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2024 & 2030
  • Table 32: Canada Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: Canada 7-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2024 & 2030
  • Table 34: Canada Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 35: Canada 7-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2024 & 2030
JAPAN
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 36: Japan Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 37: Japan 7-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2024 & 2030
  • Table 38: Japan Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Japan 7-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2024 & 2030
  • Table 40: Japan Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 41: Japan 7-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2024 & 2030
CHINA
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 42: China Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 43: China 7-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2024 & 2030
  • Table 44: China Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: China 7-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2024 & 2030
  • Table 46: China Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 47: China 7-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2024 & 2030
EUROPE
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 48: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 49: Europe 7-Year Perspective for Short-Read Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • Table 50: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: Europe 7-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2024 & 2030
  • Table 52: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 53: Europe 7-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2024 & 2030
  • Table 54: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 55: Europe 7-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2024 & 2030
FRANCE
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 56: France Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: France 7-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2024 & 2030
  • Table 58: France Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 59: France 7-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2024 & 2030
  • Table 60: France Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 61: France 7-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2024 & 2030
GERMANY
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 62: Germany Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: Germany 7-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2024 & 2030
  • Table 64: Germany Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 65: Germany 7-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2024 & 2030
  • Table 66: Germany Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 67: Germany 7-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2024 & 2030
ITALY
  • Table 68: Italy Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 69: Italy 7-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2024 & 2030
  • Table 70: Italy Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 71: Italy 7-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2024 & 2030
  • Table 72: Italy Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 73: Italy 7-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2024 & 2030
UNITED KINGDOM
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 74: UK Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 75: UK 7-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2024 & 2030
  • Table 76: UK Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 77: UK 7-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2024 & 2030
  • Table 78: UK Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 79: UK 7-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2024 & 2030
REST OF EUROPE
  • Table 80: Rest of Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 81: Rest of Europe 7-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2024 & 2030
  • Table 82: Rest of Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 83: Rest of Europe 7-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2024 & 2030
  • Table 84: Rest of Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 85: Rest of Europe 7-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2024 & 2030
ASIA-PACIFIC
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 87: Asia-Pacific 7-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2024 & 2030
  • Table 88: Asia-Pacific Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 89: Asia-Pacific 7-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2024 & 2030
  • Table 90: Asia-Pacific Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 91: Asia-Pacific 7-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2024 & 2030
REST OF WORLD
  • Table 92: Rest of World Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 93: Rest of World 7-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2024 & 2030
  • Table 94: Rest of World Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 95: Rest of World 7-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2024 & 2030
  • Table 96: Rest of World Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 97: Rest of World 7-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2024 & 2030
IV. COMPETITION

Companies Mentioned

Some of the 32 companies featured in this Global Short-Read Sequencing market report include:
  • BGI Genomics Co Ltd.
  • CD Genomics
  • Element Biosciences
  • Illumina, Inc.
  • Integra Biosciences AG
  • MedGenome, Inc.
  • Oxford Nanopore Technologies, Ltd.
  • Pacific Biosciences of California, Inc.
  • seqWell
  • Thermo Fisher Scientific, Inc.

Table Information